Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

What Was Tested

Researchers studied Octreotide in this randomized controlled trial publication.

Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant.

Who Took Part

The abstract describes 50 patients taking part.

PubMed tags the participants as both men and women.

In this randomized, double- blind placebo-controlled clinical trial, the researchers randomly assigned 50 patients who underwent deceased donor liver transplant and fulfilled the study inclusion requirements to receive either octreotide infusion for 3 days in the first 3 days after transplant in the intensive care unit or placebo.

The eligible patients were properly informed while on the transplant wait list and gave their consent to participate in the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Octreotide.

Some patients received a placebo instead of Octreotide, giving a reference point.

A time span of 3 days appears in the methods.

The rates of acute kidney injury within the first 7 days after transplant (based on KDIGO criteria), early allograft dysfunction, and nosocomial infection; total length of hospital stays and intensive care unit admissions; and intubation time were recorded and compared between the 2 groups.

What Was Measured

PubMed files the paper under topics including Acute Kidney Injury, Cross Infection, Liver Transplantation, Living Donors and Octreotide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide in 50 patients over 3 days.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation), a journal based in Turkey.

More context: the Octreotide compound page, all human trials.